Clinical trial
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients…
NCT00024427 · Wellstat Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00024427 |
|---|---|
| Title | Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer |
| Official title | An Open Label, Randomized, Controlled, Phase III, Multi-center, Clinical Trial Of PN401 With High Dose 5-Fluorouracil (5FU) Versus Gemcitabine For Treatment Of Patients With Advanced Pancreatic Cancer |
| Lead sponsor | Wellstat Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Drug/Agent Toxicity by Tissue/Organ, Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | fluorouracil, gemcitabine hydrochloride, triacetyluridine |
| Enrollment | 250 |
| Start date | Feb 1, 2001 |
| Primary completion | Feb 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 28, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: